Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boostrix Booster 10 Years After Previous Vaccination
NCT01147900Phase 4Completed
- Sponsor
- GSK
- Start
- Jun 2010
- Primary completion
- May 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) in diphtheria, Tetanus and pertussis (3 arms), sponsored by GSK. Primary endpoints: Number of Seroprotected Subjects Against Diphtheria and Tetanus, Concentrations for Anti-D and Anti-T Antibodies and 3 more. Started Jun 2010; status: completed.
02
Drugs
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT01147900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147900.